A Phase 1, Bioequivalence Study of SYR-472 25mg and 50mg Tablets

Phase 1

Completed

• Conditions: Healthy
• Interventions: Drug: SYR-472

• Registration Number: NCT02372097
• Lead Sponsor: Takeda

Brief Summary

The purpose of this study is to investigate the bioequivalence of 2 tablets of SYR-472 25 milligram (mg) and 1 tablet of SYR-472 50 mg administered to healthy adult males.

Detailed Description

Bioequivalence of 2 SYR-472 25 mg tablets and 1 SYR-472 50 mg tablet administered to healthy adult males will be investigated in a randomized, open-label, crossover study.

Study Timeline

• Study First Submitted: 2015-02-20
• Study First Submitted QC: 2015-02-20
• Study First Posted: 2015-02-26
• Study Start: 2015-03
• Primary Completion: 2015-04
• Study Completion: 2015-04
• Results First Submitted: 2016-04-08
• Results First Submitted QC: 2016-04-08
• Results First Posted: 2016-05-13
• Status Verified: 2023-12
• Last Update Submitted: 2023-12-07
• Last Update Posted: 2023-12-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 24

Inclusion Criteria

1. Participants who understand the outline of the clinical study and are capable of complying with their responsibilities as participants, as judged by the investigator or sub investigator.
2. Participants who can sign and date the informed consent form before the initiation of the study procedure.
3. Healthy Japanese adult males.
4. Participants who are 20 to 35 years of age at the time of informed consent.
5. Participants who weigh 50.0 kilogram (kg) or more with a body mass index (BMI) of 18.5 to less than 25.0 kilogram per square meter (kg/m^2) in the screening period.

Read More

Exclusion Criteria

1. Participants who were administered any investigational product within 16 weeks (112 days) before the start of the study drug administration in stage 1.
2. Participants who have received SYR-472 in the past.
3. Employees of the study site, their family members, those who are in a dependency relationship with employees of the study site involved in the conduct of the study (for example [e.g.], spouse, parents, children, brothers and sisters), and those who might be coerced to consent to participate in the study.
4. Participants who have poorly controlled, clinically significant abnormalities of the nervous system, cardiovascular system, lung, liver, kidneys, metabolism, gastrointestinal system, urinary system, or endocrinological system, which possibly may affect study participation or study results.
5. Participants who have a positive urine drug test in the screening period.
6. Participants who need to use drugs or foods listed in the table of prohibited concomitant drugs and foods.
7. Participants who have a history of hypersensitivity or allergy to drugs (including SYR-472 and its ingredients).
8. Participants who currently have or recently had (within the past 6 months) gastrointestinal disease that may affect drug absorption (malabsorption, esophageal reflux, peptic ulcer disease, erosive esophagitis, frequent [at least once a week] heartburn, surgical intervention [e.g., cholecystectomy]).
9. Participants with a past history of cancer.
10. Participants who are positive for any of the following during the screening period: hepatitis B virus surface antigen (HBsAg), antibody against hepatitis C virus (HCV), human immunodeficiency virus (HIV) antigen, anti-HIV antibody, or serological test for syphilis.
11. Participants with difficulty having blood collected from a peripheral vein.
12. Participants who donated 200 milliliter (mL) or more of whole blood within the 4 weeks (28 days) or 400 mL or more of whole blood within the 12 weeks (84 days) before starting the study drug administration in stage 1.
13. Participants who donated a total of 800 mL or more of whole blood within the 52 weeks (364 days) before starting the study drug administration in stage 1.
14. Participants who donated blood components within the 2 weeks (14 days) before starting the study drug administration in stage 1.
15. Participants who show clinically significant abnormalities in electrocardiogram (ECG) during the screening period or on Day 1 (before the study drug administration).
16. Participants who have laboratory test abnormalities suggestive of a clinically significant primary disease or who have abnormal values in any of the following parameters: alanine aminotransferase (ALT) or aspartate serum transaminase AST exceeding 1.5 times the upper limit of the normal range.
17. Participants who are unlikely to comply with the study protocol or are ineligible for the study for any other reason, as judged by the investigator or sub investigator.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Group A	SYR-472	Participants in group A will be orally administered 2 tablets of SYR-472 25 mg in period 1 and 1 tablet of SYR-472 50 mg tablet in period 2, both in a single dose under fasting conditions in the morning.
Group B	SYR-472	Participants in group B will be orally administered 1 tablet of SYR-472 50 mg in period 1 and 2 tablets of SYR-472 25 mg tablets in period 2, both in a single dose under fasting conditions in the morning.

Primary Outcome Measures

Name	Time	Method
AUC(0-168): Area Under the Plasma Concentration-Time Curve From Time 0 to 168 Hours Postdose for Unchanged SYR-472 (SYR-472Z)	Day 1: pre dose (within 3 hours prior to dosing), and at multiple time points (up to 168 hours) post dose in each period
Cmax: Maximum Observed Plasma Concentration for SYR-472Z	Day 1: pre dose (within 3 hours prior to dosing), and at multiple time points (up to 168 hours) post dose in each period

Secondary Outcome Measures

Name	Time	Method
AUC(0-inf): Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity for SYR-472Z	Day 1: pre dose (within 3 hours prior to dosing), and at multiple time points (up to 168 hours) post dose in each period
Number of Participants Reporting One or More Treatment-Emergent Adverse Events (TEAEs)	Day 1 of Period 1 up to the day of hospital discharge (Day 29) in Period 2	Collection of AEs commenced from the time that the participant was first administered study drug in Period 1 (Day 1). Routine collection of AEs continued until the end (hospital discharge) of Period 2 (Day 29).
Number of Participants With TEAEs Categorized Into Investigations System Organ Class (SOC) Related to Laboratory Values	Day 1 of Period 1 up to the day of hospital discharge (Day 29) in Period 2
Apparent Terminal Elimination Rate Constant (λz) for SYR-472Z	Day 1: pre dose (within 3 hours prior to dosing), and at multiple time points (up to 168 hours) post dose in each period
Number of Participants With TEAEs Related to Vital Signs	Day 1 of Period 1 up to the day of hospital discharge (Day 29) in Period 2
MRT: Mean Residence Time From Time Zero to Infinity for SYR-472Z	Day 1: pre dose (within 3 hours prior to dosing), and at multiple time points (up to 168 hours) post dose in each period
Tmax: Time to Reach the Cmax for SYR-472Z	Day 1: pre dose (within 3 hours prior to dosing), and at multiple time points (up to 168 hours) post dose in each period
Number of Participants With TEAEs Related to Body Weight	Day 1 of Period 1 up to the day of hospital discharge (Day 29) in Period 2
Number of Participants Who Had Abnormal and Clinically Significant 12-lead Electrocardiograms (ECG) Findings After Study Drug Administration	Baseline up to 7 days after the last dose of study drug (Day 8) in each period	Participants whose results of electrocardiograms were judged as abnormal and clinically significant by investigator after study drug administration were counted in this measure.